In preclinical murine models of melanoma, head and neck carcinoma, and neuroblastoma, it has been shown that the intratumoral injection of an immunocytokine composed of Hu14.18-IL2 can result in the complete regression of well-established tumors together with a tumor-specific T-cell memory [182]. This evidence concerns the gene IL2 and melanoma.